DanaRizkMD

Professor, Medicine, University of Alabama School of Medicine Director of Clinical Trials Research, Nephrology division Medical Director of Clinical Trials Administrative Office, UAB

Join to view full profile

Dr. Rizk is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rizk's full profile

Already have an account?

Office
1717 6th Ave S
Birmingham, AL 35233
Phone+1 800-822-8816

Fax+1 205-934-1879

Summary

Dr. Dana Rizk is a nephrologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including Birmingham Veterans Affairs Medical Center and UAB Hospital. She received her medical degree from American University of Beirut Faculty of Medicine and has been in practice 20 years. She is experienced in general nephrology, iga nephropathy, and glomerular diseases.

Education & Training

Emory University School of MedicineFellowship, Nephrology, 2001 - 2005
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 1998 - 2000
American University of Beirut Faculty of MedicineClass of 1997

Certifications & Licensure

AL State Medical License 2008 - 2024
GA State Medical License 2003 - 2009
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

MEmbranous Nephropathy Trial Of Rituximab Start of enrollment: 2011 Nov 01
Completed
Phase 2, Phase 3
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease Start of enrollment: 2013 Mar 18
Terminated
Phase 2
FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients. Start of enrollment: 2013 Aug 01
Completed
Not Applicable
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Start of enrollment: 2017 Mar 02
Completed
Phase 2, Phase 3
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™ Start of enrollment: 2017 Jun 13
Completed
Join now to see all

Publications & Presentations

PubMed

69 citations
CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease
Laura H. Mariani, Andrew S. Bomback, Pietro A. Canetta, Michael F. Flessner, Margaret E. Helmuth
American Journal of Kidney Diseases. 2019-02-01
2 citations
Primary IgA Nephropathy: New Insights and Emerging Therapies.
Haresh Selvaskandan, Kenar D Jhaveri, Dana V Rizk
Advances in Kidney Disease and Health. 2024-05-01
37 citations
Association between urinary albumin excretion and coronary heart disease in black vs white adults.
Orlando M. Gutiérrez, Yulia Khodneva, Paul Muntner, Dana V. Rizk, William M. McClellan
JAMA. 2013-08-21

Journal Articles

Prognostic Value of Myocardial Perfusion Imaging Performed Pre-Renal Transplantation: Post-Transplantation Follow-up and Outcomes
Vineeta Kumar, Ami E Iskandrian, Suzanne Oparil, Dana V Rizk, Christopher W Ives, Fadi G Hage, European Journal of Nuclear Medicine and Molecular Imaging

Lectures